Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial).
BACKGROUND
The success rate of long-term maintenance of weight loss in obese patients is usually low. To improve the success rate, determinants of long-term weight maintenance must be identified.


OBJECTIVE
The objective of the study was to identify determinants of long-term success in weight maintenance in obese subjects who completed the Sibutramine Trial on Obesity Reduction and Maintenance (n = 261), a multicenter European study of weight loss and weight maintenance in obesity that combines sibutramine treatment with dietary restriction and advice on exercise and behavior.


METHODS
We studied weight maintenance over 18 mo in subjects who had completed a 6-mo weight-loss phase. Factors included in the analysis were initial body weight, the percentage of initial body weight lost, dietary intake, various components of physical activity (measured with the Baecke questionnaire), the type of treatment (sibutramine or placebo), age, and sex.


RESULTS
Multiple regression analysis identified treatment group (sibutramine or placebo), the percentage of the initial body weight that was lost during the 6-mo weight-loss phase, and the leisure-time physical activity index as significant determinants of weight maintenance. Together, these 3 factors explained 20% of the variation in weight maintenance (P < 0.001). Dietary factors, age, and sex were not significant predictors of weight-maintenance success in this study.


CONCLUSIONS
Weight-maintenance success after weight loss is positively influenced by sibutramine treatment during weight maintenance, by a greater initial weight loss, and by a higher leisure-time physical activity index, which reflects higher levels of activities such as walking and cycling and lower levels of television viewing.
van Baak
Marleen A
MA
Department of Human Biology, Nutrition and Toxicology Research Institute, Maastricht University, Maastricht, Netherlands. m.vanbaak@hb.unimaas.nl
van Mil
Edgar
E
Astrup
Arne V
AV
Finer
Nick
N
Van Gaal
Luc F
LF
Hilsted
Jannik
J
Kopelman
Peter G
PG
Rössner
Stephan
S
James
W Philip
WP
Saris
Wim H M
WH
D000293:Adolescent; D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D003503:Cyclobutanes / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D006801:Humans; D007899:Leisure Activities; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy* / Q000628:therapy; D015431:Weight Loss
D019440:Anti-Obesity Agents; D003503:Cyclobutanes; C058254:sibutramine